Side effects such as skin aging
There are successive cases of Wegobi and Ozempic, known as the ‘dream obesity treatment’ which experience crises outside the stock, causing serious side effects in terms of hair loss.
ABC News reported on the 22nd (local time) that there are many posts about hair loss on social media from people taking anti-obesity drugs.
“To my surprise, there are no scalp symptoms, it doesn’t hurt or itch, but when I run my hand through my hair, there is a handful of hair. It’s very embarrassing to see that.”
Ohio State University dermatologist Susan Maesik, who has seen patients who have lost their hair after losing weight, said:
Semaglutide, better known by the trade names Ozempic and Wigobi, was originally made for people with type 2 diabetes. These drugs are often prescribed for weight loss. Ozempic is a diabetes treatment, and Wigobi is the obesity treatment version of Ozempic.
Hair loss is a devastating side effect, but “hair loss is relatively uncommon among people taking medication,” says Dr. Vijaya Surampudi, associate director of the Weight Management Program at the University of California, Los Angeles.
Hair loss is not listed as a side effect of Ozempig, but hair loss was reported by 3% of participants in clinical trials of Wegobi. (Ozempic and Wigobi are the same drug, but Wigobi is given at a higher dose)
Not too long ago, a side effect called ‘Ojempic Face’ was reported, where the face becomes emaciated and ages prematurely due to rapid weight loss after taking an anti-obesity drug.
Ozempic is expected to be released in Korea in the first half of this year at the earliest. Ozempic was approved by the Food and Drug Safety Administration in April last year as an adjunct to diet and exercise therapy for adults with inadequately controlled type 2 diabetes.
At a recent meeting, the Health Insurance Review and Assessment Service’s Pharmaceutical Reimbursement Evaluation Committee evaluated Ozempic Prefilled Pen (ingredient: semaglutide) as eligible for benefits.
Ozempic is a GLP-1 drug that controls blood sugar by promoting insulin secretion and inhibiting glucagon secretion. GLP-1 has a number of effects, including increasing the release of insulin from the pancreas and targeting brain receptors that reduce appetite.
